A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus

Receptor Antagonist ◽

Glucagon Receptor ◽

Glucagon Receptor Antagonist LGD-6972 Significantly Lowers HbA1c and Is Well Tolerated after 12-Week Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) on Metformin

Diabetes ◽

10.2337/db18-73-or ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 73-OR ◽

Cited By ~ 1

Author(s):

JEREMY PETTUS ◽

ERIC G. VAJDA ◽

JAMES PIPKIN ◽

GRETCHEN WILLIAMSON ◽

MIRIAM A. ZANGMEISTER ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Antagonist ◽

Glucagon Receptor ◽

Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus

10.1111/dom.12752 ◽

2016 ◽

Vol 19 (1) ◽

pp. 24-32 ◽

Cited By ~ 23

Author(s):

Eric G. Vajda ◽

Douglas Logan ◽

Kenneth Lasseter ◽

Danielle Armas ◽

Diane J. Plotkin ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Antagonist ◽

Healthy Subjects ◽

Pharmacokinetics And Pharmacodynamics ◽

Glucagon Receptor ◽

Single And Multiple Doses ◽

Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus

10.1111/dom.12672 ◽

2016 ◽

Vol 18 (8) ◽

pp. 795-802 ◽

Cited By ~ 30

Author(s):

D. J. Kazierad ◽

A. Bergman ◽

B. Tan ◽

D. M. Erion ◽

V. Somayaji ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Antagonist ◽

Glucagon Receptor ◽

The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus

Bioorganic & Medicinal Chemistry Letters ◽

10.1016/j.bmcl.2013.03.014 ◽

2013 ◽

Vol 23 (10) ◽

pp. 3051-3058 ◽

Cited By ~ 29

Author(s):

Angel Guzman-Perez ◽

Jeffrey A. Pfefferkorn ◽

Esther C.Y. Lee ◽

Benjamin D. Stevens ◽

Gary E. Aspnes ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Antagonist ◽

Glucagon Receptor ◽

Design And Synthesis ◽

Pharmacokinetic Properties ◽

In Silico Identification of Novel Glucagon Receptor Antagonist for the Treatment of Type 2 Diabetes Mellitus

Enzyme Engineering ◽

10.4172/2329-6674.1000128 ◽

2015 ◽

Vol 04 (02) ◽

Author(s):

Utkarsh Raj ◽

Yashasvi Jain ◽

Himansu Kumar

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Antagonist ◽

In Silico ◽

Glucagon Receptor ◽

Glucagon Receptor Antagonist ◽

In Silico Identification

Efficacy and safety of the glucagon receptor antagonist PF‐06291874: A 12‐week, randomized, dose‐response study in patients with type 2 diabetes mellitus on background metformin therapy

10.1111/dom.13440 ◽

2018 ◽

Vol 20 (11) ◽

pp. 2608-2616 ◽

Cited By ~ 8

Author(s):

David J. Kazierad ◽

Kristin Chidsey ◽

Veena R. Somayaji ◽

Arthur J. Bergman ◽

Roberto A. Calle

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Antagonist ◽

Dose Response ◽

Efficacy And Safety ◽

Glucagon Receptor ◽

Glucagon Receptor Antagonist ◽

Dose Response Study

Progress towards glucagon receptor antagonist therapy for Type 2 diabetes

Expert Opinion on Therapeutic Patents ◽

10.1517/13543776.15.12.1739 ◽

2005 ◽

Vol 15 (12) ◽

pp. 1739-1749 ◽

Cited By ~ 14

Author(s):

Ravi Kurukulasuriya ◽

JT Link

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Antagonist Therapy ◽

Glucagon Receptor ◽

Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

10.1111/dom.12958 ◽

2017 ◽

Vol 19 (11) ◽

pp. 1521-1528 ◽

Cited By ~ 47

Author(s):

Cristina B. Guzman ◽

Xiaotian M. Zhang ◽

Rong Liu ◽

Arie Regev ◽

Sudha Shankar ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Liver Fat ◽

Glucagon Receptor ◽

Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial

Endocrine ◽

10.1007/s12020-018-1597-1 ◽

2018 ◽

Vol 62 (2) ◽

pp. 371-380 ◽

Cited By ~ 4

Author(s):

Barry Gumbiner ◽

Brooke Esteves ◽

Vanessa Dell ◽

Tenshang Joh ◽

Pamela D. Garzone ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Controlled Trial ◽

Phase 1 ◽

Double Blind ◽

Glucagon Receptor ◽

Double Blind Placebo ◽

Dose Study ◽

DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus

Journal of Endocrinological Investigation ◽

10.1007/s40618-019-01153-z ◽

2019 ◽

Vol 43 (5) ◽

pp. 653-662

Author(s):

W. Wang ◽

X. Wen ◽

W. Duan ◽

X. Wang ◽

Y. Chen ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Glucagon Receptor ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Treatment Of Obesity ◽

Long Acting